Mast Cell Function in Diabetic Renal Pathophysiology

Mast cells are centrally implicated in the progression of diabetic kidney disease through their roles in inflammation, fibrotic remodelling and microvascular dysfunction. In the diabetic milieu, elevated glucose levels trigger mast cell activation and degranulation, resulting in release of mediators including histamine, proteases and cytokines. These factors contribute to disruption of the glomerular filtration barrier, mesangial expansion and interstitial fibrosis. Mast cell–derived histamine induces vasodilatation and increased vascular permeability, exacerbating proteinuria and promoting albuminuria through enhanced transendothelial transport. Proteolytic enzymes such as tryptase and chymase influence extracellular matrix turnover and activate latent growth factors, notably transforming growth factor β1, which drives myofibroblast differentiation and collagen deposition. Cross-talk between mast cells and resident renal cells, including podocytes and mesangial cells, further amplifies inflammatory cascades via cytokine networks such as interleukin 6 and tumour necrosis factor. Emerging evidence suggests that targeting mast cell stabilisation or specific receptor antagonism may attenuate the progression of diabetic nephropathy by preserving glomerular integrity, reducing albuminuria and mitigating fibrotic remodelling.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Research from all publishers

Recent studies have elucidated the broader significance of histamine signalling in renal homeostasis and diabetic nephropathy. A comprehensive review of histamine metabolism and receptor distribution in the kidney has highlighted how histamine release by mast cells modulates renal blood flow, glomerular filtration and inflammatory injury, suggesting that histamine receptor blockade may represent a therapeutic strategy to limit progression of diabetic kidney disease. In murine models, deletion of the histamine H4 receptor attenuates albuminuria and preserves expression of key tubular proteins such as megalin, while reducing over-expression of the sodium-hydrogen exchanger NHE3 in diabetic mice. These findings demonstrate that specific histamine receptor subtypes govern renal reabsorption processes and may be harnessed to protect against hyperglycaemia-induced nephropathy. A recent randomised clinical trial in patients with diabetic kidney disease has repurposed fexofenadine, a histamine H1 receptor antagonist, as an adjuvant to standard renin-angiotensin system inhibition. Over six months, fexofenadine reduced the urinary albumin-to-creatinine ratio by 16 percent, mitigated pro-inflammatory markers such as monocyte chemoattractant protein 1 and oxidative‐stress biomarkers, and stabilised estimated glomerular filtration rate. This study underscores the potential clinical utility of antihistamines in attenuating inflammatory and fibrotic mechanisms driven by mast cell mediators in diabetic renal pathophysiology.

Mast Cell Function in Diabetic Renal Pathophysiology publication trend

The graph below shows the total number of articles in mast cell function in diabetic renal pathophysiology across all publications each year (not limited to Nature Index journals).

Technical terms

Mast cell: A type of immune cell rich in granules containing histamine and proteases, involved in allergic and inflammatory responses.

Diabetic nephropathy: A progressive kidney disease caused by long-term diabetes, characterised by proteinuria, glomerulosclerosis and declining renal function.

Glomerular filtration barrier: The tri-layered structure of endothelial cells, basement membrane and podocytes that regulates plasma filtration in the kidney.

Albumin-to-creatinine ratio (ACR): A clinical measure of albuminuria, indicating the amount of albumin excreted in urine relative to creatinine concentration.

Histamine: A biogenic amine released by mast cells that acts on specific receptors to modulate vascular permeability and inflammatory responses.

Transforming growth factor β1 (TGF-β1): A cytokine that induces myofibroblast activation and extracellular matrix production, driving fibrotic remodelling.

References

1. The implications of histamine metabolism and signaling in renal function. Physiological Reports (2021).
2. The Interplay between Histamine H4 Receptor and the Kidney Function: The Lesson from H4 Receptor Knockout Mice. Biomolecules (2021).
3. Repurposing fexofenadine as a promising candidate for diabetic kidney disease: randomized clinical trial. International Urology and Nephrology (2023).